智通财经APP讯，长风药业(02652)发布公告，于2025年12月30日斥资83.02万港元回购2.4万股。 ...

格隆汇12月30日丨长风药业(02652.HK)公告，12月30日耗资83万港元回购2.4万股。 ...

呈交日期： 2025年12月30日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 長風藥業股份有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02652 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

长风药业(02652)发布公告，由公司主导的新型吸入式核酸药物开发项目近期获选为2025年江苏省科技 重大专项"创新生物药"项目。本项目聚焦于小核酸(siRNA)药物在肺部递送中的关键挑战，致力于推动 吸入式核酸候选药物的转化研究与临床前开发。 公司认为，本项目的入选对集团具有重要战略意义，进一步验证了集团技术平台的实力。递送技术是 siRNA肺部治疗的关键壁垒。对此，公司已自主研发出一套高效肺靶向递送系统，相关候选药物在临床 前研究中显示出良好的治疗潜力。本项目的入选，体现了相关部门及评审专家对公司与合作单位在前沿 递送技术领域联合研发能力的充分认可。公司将持续通过技术创新，致力于为患者提供更具价值的治疗 方案，并为股东创造可持续的长期回报。 本项目计划支持针对呼吸系统重大疾病(包括哮喘、慢性阻塞性肺病及肺纤维化)的吸入式核酸候选药物 研发工作。工作范围涵盖递送体系优化、药剂学与工艺开发、临床前研究，以及新药临床试验申请准 备。 ...

Core Viewpoint - The project led by the company for the development of a novel inhaled nucleic acid drug has been selected as a major technological project in Jiangsu Province for 2025, focusing on innovative biopharmaceuticals [1] Group 1: Project Overview - The project addresses key challenges in the pulmonary delivery of small nucleic acid (siRNA) drugs and aims to advance the translational research and preclinical development of inhaled nucleic acid candidates [1] - The project plans to support the research and development of inhaled nucleic acid candidates targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis [1] Group 2: Strategic Importance - The selection of this project is considered strategically significant for the company, further validating the strength of its technological platform [1] - Delivery technology is identified as a critical barrier for siRNA treatments in the lungs, and the company has developed an efficient lung-targeted delivery system [1] Group 3: Research and Development - The project encompasses the optimization of delivery systems, formulation and process development, preclinical research, and preparation for new drug clinical trial applications [1] - The candidates developed under this project have shown promising therapeutic potential in preclinical studies [1] - The recognition from relevant departments and expert reviewers highlights the company's collaborative research capabilities in advanced delivery technology [1]

公司认为，本项目的入选对集团具有重要战略意义，进一步验证了集团技术平台的实力。递送技术是 siRNA肺部治疗的关键壁垒。对此，公司已自主研发出一套高效肺靶向递送系统，相关候选药物在临床 前研究中显示出良好的治疗潜力。本项目的入选，体现了相关部门及评审专家对公司与合作单位在前沿 递送技术领域联合研发能力的充分认可。公司将持续通过技术创新，致力于为患者提供更具价值的治疗 方案，并为股东创造可持续的长期回报。 本项目计划支持针对呼吸系统重大疾病(包括哮喘、慢性阻塞性肺病及肺纤维化)的吸入式核酸候选药物 研发工作。工作范围涵盖递送体系优化、药剂学与工艺开发、临床前研究，以及新药临床试验申请准 备。 智通财经APP讯，长风药业(02652)发布公告，由公司主导的新型吸入式核酸药物开发项目近期获选为 2025年江苏省科技重大专项"创新生物药"项目。本项目聚焦于小核酸(siRNA)药物在肺部递送中的关键 挑战，致力于推动吸入式核酸候选药物的转化研究与临床前开发。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 公司主導項目入選2025年江蘇省科技重大專項「創新生物藥」項目 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以知會股東及潛在投資者有關本集團之最新研發進展。 CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 戰略意義 本公司董事（「董事」）會（「董事會」）欣然宣佈，由本公司主導之新型吸入式核酸 藥物開發項目（「項目」）近期獲選為2025年江蘇省科技重大專項「創新生物藥」項 目。 項目詳情與發展 本項目聚焦於小核酸（「siRNA」）藥物在肺部遞送中的關鍵挑戰，致力於推動吸入 式核酸候選藥物的轉化研究與臨床前開發。 本項目計劃支持針對呼吸系統重大疾病（包括哮喘、慢性阻塞性肺病及肺纖維化） 的吸入式核酸候選藥物研發工作。工作範圍涵蓋遞送體系優化、藥劑學與工藝開 發、臨床前研究，以及 ...

Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration (NMPA) for its clinical trial application of the fixed combination nasal spray, Olopatadine Mometasone, marking a significant step in its clinical development process [1][2] Group 1: Product Development - The product is a self-developed fixed combination nasal spray aimed at treating moderate to severe allergic rhinitis in specific age groups [1] - The formulation combines an antihistamine (Olopatadine) for allergy symptoms and a corticosteroid (Mometasone) for inflammation-related symptoms, potentially offering a convenient treatment option for patients who do not respond well to single therapies [1][2] - The fixed combination formulation is designed to reduce the need for patients to use multiple products, thereby enhancing medication convenience and adherence [1] Group 2: Strategic Importance - Advancing this product is deemed significant for expanding the company's nasal care product portfolio, potentially providing broader treatment options for moderate to severe patients upon approval [2] - The project highlights the company's R&D capabilities in nasal suspension formulations and drug-device integration, which typically have higher technical barriers and quality requirements compared to standard formulations [2] - Once approved, the product could complement the existing respiratory and nasal product lineup, strengthening market coverage in the airway disease treatment sector [2]

Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration (NMPA) for its clinical trial application of the self-developed fixed combination nasal spray, Olopatadine Mometasone, marking the start of regulatory review for potential clinical development [1][2] Group 1: Product Development - The product is a fixed combination nasal spray designed to treat moderate to severe allergic rhinitis in specific age groups, combining an antihistamine and a corticosteroid in a single formulation [1] - The clinical research aims to evaluate whether this fixed combination can provide a convenient treatment option for patients whose symptoms are not effectively controlled by monotherapy [1] Group 2: Strategic Importance - Advancing this product is significant for the company as it will expand the allergy and rhinitis product line, offering broader treatment options for moderate to severe patients, depending on the approved label [2] - The project highlights the company's R&D capabilities in nasal suspension formulations and drug-device integration, which typically have higher technical barriers and quality requirements compared to standard formulations [2] Group 3: Market Positioning - Once approved, the product is expected to complement the existing respiratory and nasal product portfolio, enhancing market coverage in the field of airway disease treatment [2] - The company will maintain communication and cooperation with NMPA during the review process and comply with relevant laws and regulations [2]

Core Viewpoint - Changfeng Pharmaceutical (02652.HK) has received a notice of acceptance from the National Medical Products Administration (NMPA) for its clinical trial application of the self-developed fixed combination formulation, Olopatadine Mometasone nasal spray, marking a significant step in its clinical development process [1] Group 1: Product Information - Product Name: Olopatadine Mometasone nasal spray [1] - Application Type: Domestic production drug registration clinical trial [1] - Indication: Treatment of moderate to severe allergic rhinitis symptoms in adults and adolescents aged 12 and above [1] Group 2: Clinical Development - The acceptance of the clinical trial application signifies the product's entry into the regulatory review phase for potential clinical development by NMPA [1] - The clinical research aims to evaluate whether this fixed combination formulation can provide a convenient treatment option for patients whose symptoms are not effectively controlled by single therapies [1] Group 3: Strategic Alignment - This milestone aligns with the company's strategy to establish a differentiated portfolio of respiratory and nasal products [1] - The company intends to leverage its formulation, device integration, and manufacturing capabilities in the field of nasal drug-device combination products [1]